medigraphic.com

2008, Number 4

<< Back Next >>

Enf Infec Microbiol 2008; 28 (4)

Inmune response to rubella vaccine in VIH adult patients with HAART

García LML, Wong CRM, Belaunzarán ZPF, Cuéllar RJ, Mosqueda GJL, Escobedo K, Villasís KA, Santos PJI, Ruiz PGM, Sierra MJG

Language: Spanish
References: 29
Page: 130-135
PDF size: 249.12 Kb.


ABSTRACT

Background. There is limited information about the immune response to rubella re-vaccination in HIV infected adults with immune recovery as a result of highly active antiretroviral therapy.
Methods. We conducted a clinical trial to evaluate the immune response to rubella vaccine in HIV-infected adults. MMR vaccine was given to HIV-infected and non-infected adults. The immune response was determined by serum IgG antibodies before, three and 12 months after vaccination. Adverse effects were assessed at baseline, three and 12 months after vaccination.
Results. MMR vaccine was administered to 26 HIV-infected and 25 HIV-non infected subjects. No severe adverse events were reported. The seropositivity to rubella before vaccination was 95% in HIV-infected adults and 90% in healthy adults, three months after vaccination, two healthy adults seronegative to rubella seroconverted 25/25 (100%), as well as the only adult with HIV seronegative to rubella 26/26 (100%). One year after vaccination, 100% of the HIV-infected adults remained seropositive to rubella compared to 95% in non-infected adults.
Conclusions. Seropositivity to rubella in HIV-infected adults in Mexico is high, a re-immunization with rubella produces a booster response in HIV infected and HIV-non-infected adults with low titers of antibodies, which persists for at least 1 year.


REFERENCES

  1. Murphy FA et al. “Virus taxonomy, 6th report of the International Committee on Taxonomy of Viruses (ICTV)”. Arch Virol Suppl 1995, 1-586.

  2. Lee JY Bowden, DS. “Rubella virus replication and links to teratogenicity”. Clin Microbiol Rev 2000:13; 571-587.

  3. World Health Organization. “Rubella vaccines. WHO position paper”. Wkly Epidemiol Rec 2000 75, 161-169.

  4. SUIVE/DGE/Secretaría de Salud/Estados Unidos Mexicanos, 2005.

  5. Annual WHO/UNICEF Joint Reporting Form and WHO regional offices reports, actualización a diciembre de 2006.

  6. WHO/IVB base de datos, 192 WHO Member States, datos hasta agosto de 2006.

  7. Watson JC, Hadler SC y Dykewicz CA “Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committe on Immunization Practices (ACIP)”. MMWR 1998:47; 1-57.

  8. “Expanded Programme on Immunization (EPI)”. Wkly Epidemiol Rec 1996:71; 305-312.

  9. Just M, Just V, Berger R, Burkhardt F y Schilt U. “Duration of immunity after rubella vaccination: a long-term study in Switzerland”. Rev Infect Dis 1985:S7, S91-S94.

  10. Centers for disease control and prevention. “Measles prevention: recommendations of the Immunization Practices Advisory Committe (ACIP)”. MMWR 1989:38 (S-9):1-18.

  11. Immunization Practices Advisory Committee. “Immunization of children infected with human immunodeficiency virus: Suplementary ACIP statement”. MMWR 1988:37;181-186.

  12. “Centers for disease control and prevention. Measles, Rubella, and Congenital Rubella Syndrome − United States and Mexico, 1997−1999”. MMWR 2000: 49; 1048-1050,1059.

  13. Lederman MM et al. “Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315”. J Infect Dis 1998:178; 70-79.

  14. Melvin AJ y KM, M. “Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy”. Pediatrics 2003:111(6); e641-e644.

  15. Aurpibul L, Puthanakit T, Sirisanthana T y V, S. “Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy”. Clin Infect Dis 2007:45; 637-642.

  16. Gutiérrez Trujillo G et al. “The seroepidemiology of rubella in Mexican women. A national probability survey”. Salud Pública Mex 1990: 32; 623-631.

  17. Villaseñor-Sierra. A et al. “Antibody development and frequency of events temporarily associated with measles and rubella vaccines among university health personnel in Jalisco”. Gac Méd Mex 2005:141; 455-459.

  18. Villasis-Keever MA et al. “Prevalence of serological markers against measles, rubella, varicella, hepatitis B, hepatitis C, and human immunodeficiency virus among medical residents in Mexico”. Prev Med 2001:32; 424-8 .

  19. American, Academy & Pediatrics. “Measles”, en: Pickering LK. Report of the Committee on Infectious Diseases, 26a ed, Elk Grove Village, IL, American Academy of Pediatrics 2003, 419-429.

  20. Centers for Disease Control and Prevention. “1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age”. MMWR 1994:43; 1-19.

  21. Lima M, De Menezes Succi RC, Nunes Dos Santos AM, Weckx LY y De Moraes-Pinto MI. “Rubella immunization in human immunodeficiency virus type 1-infected children: cause for concern in vaccination strategies”. Pediatric Infect Dis J 2004:23; 604-607.

  22. Frenkel LM, Nielsen K, Garakian A y Cherry JDA, “Search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection”. Arch Pediatr Adolesc Med 1994:148; 57-60.

  23. Echeverria Lecuona J, Aldamiz-Echevarria Azuara L, Cilla Eguiluz, G y Pérez Trallero E. “Responses to triple viral and tetanus vaccination in HIV-infected children”. An Esp Pediatr 1996:44; 317-320.

  24. Sprauer MA et al. “Response of human immunodeficiency virus-infected adults to measles-rubella vaccination”. J Acquir Immune Defic Syndr 1993:6; 1013-1016.

  25. Arpadi SM et al. “Measles antibody in vaccinated human immunodeficiency virus type 1-infected children”. Pediatrics 1996:97; 653-657.

  26. Hilgartner MW et al. “Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development Study”. Am J Hematol 2001:66; 92-98.

  27. Bekker V et al. “Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy-Treated Children with HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection”. Pediatrics 2006:118; 315-322.

  28. De Milito A. “B lymphocyte dysfunctions in HIV infection”. Curr HIV Res 2004:2; 11-21.

  29. Titanji K et al. “Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection”. Blood 2006:108; 1580-7.




2020     |     www.medigraphic.com